- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Infectious Diseases
Volume 2012 (2012), Article ID 841834, 4 pages
A Mysterious Gram-Positive Rods
Department of Internal Medicine, MedStar Harbor Hospital, 3001 South Hanover Street, Baltimore, MD 21225, USA
Received 29 March 2012; Accepted 8 July 2012
Academic Editors: L. M. Bush, V. Misra, S. Talhari, and W. I. van der Meijden
Copyright © 2012 Javzandulam Natsag et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encountered a patient with a history of intravenous drug use presenting with fever, malaise and nausea who was found to have cavitary lung lesions. Unexpectedly, gram positive rods grew out on day five on multiple blood cultures, which were later identified as Mycobacterium fortuitum. The patient underwent transesophageal echocardiogram, which showed aortic and tricuspid valve vegetations. Liver biopsy demonstrated granulomatous hepatitis. Interestingly, serum alkaline phosphatase level fell with antibiotic treatment. Mycobacterium fortuitum is ubiquitous worldwide, being found in tap water, and soil. M. fortuitum is usually considered as a contaminant. Disseminated infection caused by this bacterium in an immunocompetent host is extremely rare. Most of the disseminated infections have been reported in immune-deficient patients. In immunocompetent people, M. fortuitum causes human infection primarily by direct inoculation, including localized post-traumatic and surgical wound infections, and catheter-related sepsis. Our patient, an HIV-negative intravenous drug user, had Mycobacterium fortuitum sepsis associated with infective endocarditis, septic pulmonary emboli, and granulomatous hepatitis. Interestingly, the patient admitted using tap water occasionally for mixing heroin when her sterile water ran out, which we thought was the likely source of M. fortuitum.
We encountered a patient with a history of intravenous drug use (IDU) presenting with fever, malaise, and nausea who was found to have cavitary lung lesions. Unexpectedly, gram positive rods (GPR) grew out on day five blood cultures, leading us on a whirlwind adventure to the right diagnosis and treatment.
A 49-year-old female with active intravenous heroin use was admitted with fever, chills, night sweats, malaise, nausea, and 15 lb weight loss for 2 months. About a month prior to admission, the patient had a foul smelling, draining skin abscess in the left arm at the site of heroin injection, which was treated with a course of trimethoprim/sulfamethoxazole prescribed in the emergency room. Although the abscess resolved, her constitutional symptoms worsened. She reported no cough, vomiting, diarrhea, abdominal pain, or dysuria and was taking no regular medications. She used heroin daily and had a twenty pack-year smoking history. She had been incarcerated for 9 months about five years prior to admission.
On physical examination, the patient was cachectic and malnourished. She was awake, alert, fully oriented and in no acute distress. Temperature was 39.4°C, blood pressure 115/69, heart rate 127, respiratory rate 20, and oxygen saturation 99% on ambient air. The area of the previous injection site infection was healed. Multiple needle track marks in the cubital fossae were noted. There was no cervical and axillary lymphadenopathy, and the lungs were clear to auscultation. Cardiovascular exam showed a regular tachycardia with normal S1 and S2. There were no murmurs or extra heart sounds. Abdominal exam was significant for mild right-upper-quadrant tenderness to deep palpation and a liver span of 14 cm in the right midclavicular line.
Laboratory showed a leukocytosis of 11.2, a markedly elevated serum alkaline phosphatase of 1210 unit/L (normal 38–126) and gamma-glutamyl transpeptidase (GGT) 957 unit/L (normal 12–43), as well as slightly elevated AST 125 unit/L, ALT 55 unit/L, and total bilirubin 1.5 mg/dL with direct bilirubin 0.9 mg/dl. Chest X-ray showed a nodule in the left lower lung. Intravenous contrast-enhanced chest CT demonstrated a peripheral 1.7 cm cavitary nodule in the left lower lobe and a peripheral 3 cm mass-like infiltrate in the right lower lobe (Figure 1). Abdominal ultrasound demonstrated hepatomegaly without focal abnormality. The patient was empirically started on vancomycin for suspected staphylococcal endocarditis and was placed on respiratory isolation for possible tuberculosis. Since the patient did not produce sputum, bronchoscopy was performed, and an AFB smear as well as bronchoalveolar lavage culture were negative. Transthoracic echocardiogram showed normal systolic function without vegetation. Hepatitis C serology was positive, and HIV was negative. The patient continued to be febrile and tachycardic on day 3, her blood pressure fell to 85/44, and piperacillin/tazobactam was added to vancomycin, along with intravenous fluid resuscitation. Although blood culture was negative initially, gram positive rods, which appeared to be branching, were grown in multiple cultures after 5 days. Nocardia was suspected, therefore, trimethoprim/sulfamethoxazole (TMP/SMX) was started, and vancomycin and piperacillin/tazobactam were continued. Subsequently, the infectious disease consult recommended switching from vancomycin to linezolid to cover adequately for possible disseminated Nocardia infection. Therefore, the patient was placed on linezolid, piperacillin/tazobactam, and TMP/SMX. After the antibiotics regimen was initiated, the patient became afebrile and normotensive and felt much better. On day 14, the patient was discharged home with oral linezolid and TMP/SMX; however, she failed to keep her follow-up appointment and did not take her medications. She was readmitted 14 days later with the recurrence of all prior symptoms.
Approximately 15 days after the first admission, the reference lab reported that the gram positive rods were also acid fast and identified them as Mycobacterium fortuitum. The organism was grown in 6 aerobic bottles of a total of 15 blood cultures obtained during the two hospital admissions. It was sensitive to linezolid, imipenem, ciprofloxacin, amikacin, doxycycline, and sulfamethoxazole; and was resistant to clarithromycin, cefoxitin, and tobramycin. During the second admission, the patient was placed on intravenous linezolid and ciprofloxacin, and oral TMP/SMX with clinical improvement. She underwent transesophageal echocardiogram, which showed aortic and tricuspid valve vegetations (Figure 2). A liver biopsy showed granulomatous hepatitis (Figure 3). No organisms could be identified on the liver biopsy culture. However, serum alkaline phosphatase level fell with antibiotic treatment (Figure 4).
The patient completed a six-week course of intravenous antibiotics and was discharged on oral bactrim and ciprofloxacin with goal of continuing the antibiotics for 6–12 months. She was counseled regarding options for treating her narcotic addiction.
Mycobacterium fortuitum is ubiquitous worldwide, being found in tap water, soil, and dust . It belongs to the rapidly-growing nontuberculous mycobacteria group, growing in culture within a week, rapidly as compared to other mycobacteria . M. fortuitum is usually considered as a contaminant . Disseminated infection caused by this bacterium in an immunocompetent host is extremely rare. Most of the disseminated infections have been reported in immune-deficient patients . In immunocompetent people, M. fortuitum causes human infection primarily by direct inoculation, including localized posttraumatic and surgical wound infections, and catheter-related sepsis [1–3]. Rarely, other infections occur such as keratitis, prosthetic valve endocarditis, cervical lymphadenitis, and pulmonary disease [2, 3]. Our patient, an HIV-negative intravenous drug user, had Mycobacterium fortuitum sepsis associated with infective endocarditis, septic pulmonary emboli, and granulomatous hepatitis.
Our patient most likely became infected with M. fortuitum through intravenous drug use, with bacteremia and endocarditis. Upon further questioning, the patient was found to be enrolled in the needle exchange program, which provides sterile needles, water, and bleach for IDU in the city of Baltimore. Our patient reported having been meticulous in following aseptic rules. For instance, when she ran out of sterile needles, she cleaned her used needles with bleach. However, she occasionally used tap water for mixing heroin when sterile water ran out. Interestingly, tap water is one of the common sources of M. fortuitum. Moreover, mycobacterium is resistant to low concentration of bleach. Therefore, our patient likely was selectively injecting M. fortuitum, rather than the more common Staphylococcus aureus, which would have been killed by the bleach and not generally present in tap water.
Endocarditis caused by M. fortuitum is rare , with only 20 cases having been reported to date . In the majority of these cases, the infection occurred on prosthetic valves, both mechanical and biologic . Native valve endocarditis caused by this organism is even rarer, with only 4 cases reported to date [5–8] (Table 1). Our case is the fourth case report of M. fortuitum granulomatous hepatitis [9–11] and the second case report of M. fortuitum double native valve endocarditis . Moreover it is the first case report of M. fortuitum native valve endocarditis and granulomatous hepatitis—presenting in the same patient.
M. fortuitum is a thin, branching, and gram positive bacillus. Nocardia is typically the first organism suspected when branching gram positive bacilli are identified, which can lead to a delay in proper therapy . Ziehl-Nielsen acid-fast stain can be helpful to differentiate these organisms. However, rapidly growing mycobacteria are more easily decolorized by acid alcohol, a property that makes them more difficult to stain than the slowly growing mycobacteria [12, 13]. As result, acid-fast stain can be variable.
Empiric treatment for severe disseminated M. fortuitum includes parenteral amikacin plus two of the following drugs: tobramycin, cefoxitin, and levofloxacin. An alternative is that a combination of all three of the latter drugs may be used. Susceptibility testing is very important in choosing antibiotics because of differences in susceptibilities among species of rapidly growing mycobacterium. For severe disease, at least two agents to which the M. fortuitum isolate is susceptible should be initiated and continued for 2–6 weeks until clinical improvement is evident, followed by oral therapy with two effective agents for 6–12 months .
Mycobacterium species should be included in the differential diagnosis of GPR bacteremia in patients with history of intravenous drug use, as well as catheter, and dialysis-related sepsis. AFB stain can be helpful if branching GPRs are identified in the aerobic bottles of the blood smear. Granulomatous hepatitis, which could develop secondary to mycobacterial bacteremia, presents with disproportionate elevation of the serum alkaline phosphatase.
No potential conflicts of interest or funding exist. The paper was presented at American College of Physicians in the Annual Meeting 2011 in San Diego, CA.
- B. A. Brown-Elliott and R. J. Wallace Jr., “Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria,” Clinical Microbiology Reviews, vol. 15, no. 4, pp. 716–746, 2002.
- D. E. Griffith and R. J. Wallace Jr., Rapidly Growing Mycobacterial Infections in HIV-Negative Patients: UpToDate, 2009.
- R. J. Wallace Jr., J. M. Swenson, V. A. Silcox, R. C. Good, J. A. Tschen, and M. S. Stone, “Spectrum of disease due to rapidly growing mycobacteria,” Reviews of Infectious Diseases, vol. 5, no. 4, pp. 657–679, 1983.
- J. Olalla, M. Pombo, J. M. Aguado et al., “Mycobacterium fortuitum complex endocarditis—case report and literature review,” Clinical Microbiology and Infection, vol. 8, no. 2, pp. 125–129, 2002.
- S. P. Collison and N. Trehan, “Native double-valve endocarditis by Mycobacterium fortuitum following percutaneous coronary intervention,” Journal of Heart Valve Disease, vol. 15, no. 6, pp. 836–838, 2006.
- D. W. Spell, J. G. Szurgot, R. W. Greer, and J. W. Brown III, “Native valve endocarditis due to Mycobacterium fortuitum biovar fortuitum: case report and review,” Clinical Infectious Diseases, vol. 30, no. 3, pp. 605–606, 2000.
- M. Singh, A. Bofinger, G. Cave, and P. Boyle, “Mycobacterium fortuitum endocarditis in a patient with chronic renal failure on hemodialysis,” Pathology, vol. 24, no. 3, pp. 197–200, 1992.
- M. T. Kuruvila, P. Mathews, M. Jesudason, and A. Ganesh, “Mycobacterium fortuitum Endocarditis and Meningitis after Balloon Mitral Valvotomy,” Journal of Association of Physicians of India, vol. 47, no. 10, pp. 1022–1023, 1999.
- D. P. Brannan, R. E. DuBois, M. J. Ramirez, M. J. Ravry, and E. O. Harrison, “Cefoxitin therapy for Mycobacterium fortuitum bacteremia with associated granulomatous hepatitis,” Southern Medical Journal, vol. 77, no. 3, pp. 381–384, 1984.
- J. Montoliu, J. M. Gatell, and J. Bonal, “Disseminated visceral infection with Mycobacterium fortuitum in a hemodialysis patient,” American Journal of Nephrology, vol. 5, no. 3, pp. 205–211, 1985.
- C. W. Ingram, D. C. Tanner, D. T. Durack, G. W. Kernodle Jr., and G. R. Corey, “Disseminated infection with rapidly growing mycobacteria,” Clinical Infectious Diseases, vol. 16, no. 4, pp. 463–471, 1993.
- M. B. Smith, V. J. Schnadig, M. C. Boyars, and G. L. Woods, “Clinical and pathologic features of Mycobacterium fortuitum infections: an emerging pathogen in patients with AIDS,” American Journal of Clinical Pathology, vol. 116, no. 2, pp. 225–232, 2001.
- E. J. McFarland and D. R. Kuritzkes, “Clinical features and treatment of infection due to Mycobacterium fortuitum/chelonae complex,” Current Clinical Topics in Infectious Diseases, vol. 13, pp. 188–202, 1993.